Yinno Pharma-B(02591.HK)Proposes to Implement H-Share Full Circulation Plan

Gelonghui March 17 — Silver Nuo Medicine-B (02591.HK) announced that, according to the “Guidelines,” on March 17, 2026, the company has submitted a filing application to the China Securities Regulatory Commission (CSRC) to convert all of its domestic unlisted shares into H-shares. After obtaining all relevant approvals and/or filings (including the CSRC filing notice and the approval from the Hong Kong Stock Exchange) and complying with all applicable laws, rules, and regulations, these domestic non-listed shares will be converted into H-shares. The company will then apply for approval to list and trade these H-shares on the Main Board of the Hong Kong Stock Exchange (“conversion and listing”). According to the company’s articles of association, no shareholder approval is required for the conversion and listing.

As of the date of this announcement, the company has not yet completed the CSRC filing process, and the detailed implementation plan for the conversion and listing has not been finalized. The conversion and listing still require compliance with additional procedures mandated by the CSRC, the Hong Kong Stock Exchange, and other relevant domestic and international regulatory authorities.